share_log

方盛制药(603998.SH):产品拟中选全国中成药采购联盟集中带量采购

Hunan Fangsheng Pharmaceutical (603998.SH): The products are expected to be selected for the national Chinese Patent Medicine procurement alliance's centralized volume procurement.

Gelonghui Finance ·  Jan 2 17:49

On January 2, Gelonghui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that the company and its subsidiary Hunan Xiangya Pharmaceutical Co., Ltd. (referred to as 'Xiangya Pharmaceutical') participated in the national Chinese Patent Medicine procurement alliance centralized procurement work. According to the announcement released by the Hubei Medical Insurance Service Platform on the evening of December 30, 2024, the proposed selection results for the national Chinese Patent Medicine procurement alliance centralized procurement (first batch expansion continuation) indicate that Xuesaitong tablets are among the proposed selected products.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment